Jian Zhao

USPTO Granted Patents = 49 (Patent Applications = 30)

EPO Patents = 7 (Patent Applications = 21)

Average Co-Inventor Count = 3.0

ph-index = 10

Forward Citations = 392(Granted Patents)

Location History:

Montrose, CA (US) (2014 - 2017)
San Diego, CA (US) (2015 - 2023)

Company Filing History:

Crinetics Pharmaceuticals, Inc.

patents

1 out of 4,883

Asml Netherlands B.v.

patents

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

49 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12479828 - Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof (2025-11-25),

2. 12445696 - Psycho-visual-model based video watermark gain adaptation (2025-10-14),

3. 12134610 - Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof (2024-11-05),

4. 11608335 - Somatostatin modulators and uses thereof (2023-03-21),

5. 11566015 - Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof (2023-01-31),

6. 11479540 - Nonpeptide somatostatin type 5 receptor agonists and uses thereof (2022-10-25),

7. 11468149 - Device authentication in collaborative content screening (2022-10-11),

8. 11414397 - Somatostatin modulators and uses thereof (2022-08-16),

9. 11368766 - System and method for signaling security and database population (2022-06-21),

10. 11297398 - Watermark-based metadata acquisition and processing (2022-04-05),

11. 11028068 - Somatostatin modulators and uses thereof (2021-06-08),

12. 10981894 - Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof (2021-04-20),

13. 10875839 - Somatostatin modulators and uses thereof (2020-12-29),

14. 10820065 - Service signaling recovery for multimedia content using embedded watermarks (2020-10-27),

15. 10766877 - Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof (2020-09-08),

Title: Innovator Spotlight: Jian Zhao - Pioneering Pharmaceutical Solutions

Introduction:

Jian Zhao, a visionary inventor based in San Diego, CA, has made a significant mark in the field of pharmaceuticals with his groundbreaking patents and cutting-edge research. With a total of 46 patents to his name, Zhao's innovative work has revolutionized the treatment of various medical conditions.

Latest Patents:

Two of Jian Zhao's latest patents showcase his expertise in somatostatin and melanocortin subtype-2 receptor (MC2R) modulation. The first patent focuses on somatostatin modulators, highlighting their potential in treating a range of conditions that benefit from somatostatin activity. The second patent delves into MC2R antagonists and their uses in addressing diseases that require MC2R modulation.

Career Highlights:

Having worked with esteemed companies in the pharmaceutical industry, Jian Zhao has honed his skills and expertise over the years. He has made significant contributions during his tenure at Verance Corporation and Crinetics Pharmaceuticals, Inc., where he played a pivotal role in driving innovation and research forward.

Collaborations:

Throughout his career, Jian Zhao has collaborated with accomplished professionals in the field of pharmaceuticals. Notable coworkers include Joseph M. Winograd and Rade Petrovic, who have worked alongside Zhao to bring forth novel solutions and advancements in drug development.

Conclusion:

In conclusion, Jian Zhao stands out as a trailblazing inventor whose relentless pursuit of innovation has shaped the landscape of pharmaceutical research. His prolific work in developing somatostatin and MC2R modulators underscores his commitment to improving healthcare outcomes and addressing unmet medical needs. Jian Zhao's legacy as a visionary inventor continues to inspire the next generation of researchers and innovators in the field of pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.